SpyBiotech featured in The Guardian Value of Vaccines supplement

Published on 25 Jun 2021

New technology platform helps accelerate vaccine generation

SpyBiotech has today been featured in The Guardian’s Value of Vaccines supplement, discussing the technological solutions we have developed to accelerate vaccine generation for COVID-19 variants and potentially a range of other diseases for which there are no approved treatments.

“The COVID-19 vaccine uses SpyBiotech’s unique protein “superglue” technology to display the SARS Cov-2 spike protein receptor binding domain on the surface of the Hepatitis-B virus-like particles,” stated Chief Executive Officer & Chief Scientific Officer of SpyBiotech, Sumi Biswas.